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Immunoglobulin free light chains 
in adult atopic dermatitis patients do not 
correlate with disease severity
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Abstract 
Background: Although total IgE levels have been proposed as a biomarker for disease severity in atopic dermatitis 
(AD) and are increased in the majority of AD patients, they do not correlate with disease severity during short‑term 
follow‑up. During the synthesis of immunoglobulins, free light chains (Ig‑FLCs) are produced in excess over heavy 
chains. In comparison with IgE molecules, Ig‑FLCs have a very short serum half‑life. Therefore, Ig‑FLCs might be more 
suitable as a biomarker for disease severity during follow‑up. Recent studies showed increased serum levels of kappa 
Ig‑FLCs in infants with AD, correlating with disease severity. The aim of this study was to investigate serum kappa Ig‑
FLC levels in adults with AD, and their correlation to disease severity.
Methods: Serum kappa If‑FLC and total IgE levels were measured in 82 moderate to severe AD patients and 49 non‑
atopic controls. Blood was collected from patients before start of treatment with potent topical steroids (European 
classification: III–IV). 32 patients were treated during a clinical admission, and in this subpopulation a second blood 
sample was taken after 2 weeks of treatment. Clinical severity was determined by the Six Area Six Sign Atopic Derma‑
titis (SASSAD) severity score and a panel of serum biomarkers, including thymus and activation‑regulated chemokine 
(TARC).
Results: Serum kappa Ig‑FLCs levels in adult AD patients were not increased compared to non‑atopic controls. More‑
over, we observed no correlation between kappa Ig‑FLC serum levels and disease severity determined by SASSAD and 
a panel of serum biomarkers, including TARC. Serum kappa Ig‑FLC levels did also not decrease during treatment.
Conclusion: There are no differences in serum kappa Ig‑FLC levels between adult patients suffering from moderate 
to severe AD compared to non‑atopic controls. Moreover, serum levels of kappa Ig‑FLCs cannot be used as a bio‑
marker for disease severity in adult AD.
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Background
Atopic dermatitis (AD) is the most common chronic 
inflammatory skin disease worldwide [1]. The pathogen-
esis of AD is multifactorial and involves genetic, immu-
nologic and environmental factors [2].
The role of total IgE in the pathogenesis of AD is con-
troversial. Although the majority of AD patients have 
highly increased total IgE levels, these levels do not 
correlate with disease severity [3]. During the synthesis 
of immunoglobulins, light chains are produced in excess 
over heavy chains [4, 5]. Whereas the serum half-life of 
IgE molecules is two days, the serum half-life of immu-
noglobulin free light chains (Ig-FLCs) is only 2–3  h [6]. 
Considering the relapsing and remitting course of AD, 
this might make Ig-FLCs levels more suitable as a bio-
marker for disease severity than total IgE. Ig-FLCs have 
long been considered meaningless spillover from produc-
tion of immunoglobulins. However, recent data suggest 
that Ig-FLCs might convey various biological activities 
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were found in the serum of infants with severe AD com-
pared to infants without AD [5, 6]. Moreover, in a cohort 
of children with severe AD, levels of Ig-FLCs correlated 
with disease activity [5].
These reports prompted us to investigate the role of 
serum kappa Ig-FLCs in adult AD. In this study, serum 
levels of kappa Ig-FLCs did not differ significantly 
between adult AD patients and non-atopic controls. In 
addition, both kappa Ig-FLC and total IgE levels did not 
correlate with disease severity.
Methods
Patients and controls
In a retrospective cohort study, 82 patients (50 female; 
16–65  years) with moderate to severe AD visiting the 
UMC Utrecht were included. Patients were diagnosed 
according to the criteria of Hanifin and Rajka [7]. Dis-
ease severity was assessed using the Six Area Six Sign 
Atopic Dermatitis (SASSAD) score (median 21, IQR: 
11–32), and Body Surface Area (BSA; median 33%, 
IQR: 17–53). After blood was taken, all patients were 
treated with potent topical steroids (European clas-
sification: III–IV), 32/82 of whom were treated during 
a clinical admission. Patients using oral immunosup-
pressive medications were excluded. A total of 49 age- 
and sex-matched non-atopic controls (25 female; age 
22–66  years) that did not suffer from any skin disease 
were included.
From the 32 patients that were admitted to the clinic, 
a second blood sample was taken after a median inter-
val of 11.5  days (IQR: 9.0–13.8). Protocols of this study 
were approved by the Institutional Review Board of the 
UMC Utrecht, adhering to the Declaration of Helsinki 
Principles.
Serum kappa Ig‑FLC and total IgE
A fully automated customized kappa Ig-FLC research 
assay based on ELISA technology was developed (Phadia 
Thermo Fisher, Uppsala, Sweden) for the Phadia 250® 
instrument. Kappa Ig-FLC values ≥19.4 µg/ml were con-
sidered elevated [8]. A fully automated allergy-testing 
system (Phadia Thermo Fisher) was used for measure-
ments of total IgE [9].
Serum biomarkers for disease severity
In addition to clinical severity determined by SASSAD 
and BSA, disease severity of the 32 admitted patients was 
assessed by a recently described panel of serum biomark-
ers [10]. Therefore, serum levels of thymus and activa-
tion-regulated chemokine (TARC/CCL17), pulmonary 
and activation-regulated chemokine (PARC/CCL18), sIL-
2R and IL-22 were measured using Multiplex immunoas-
says at the MultiPlex Core Facility of the Laboratory for 
Translational Immunology (UMC Utrecht, The Nether-
lands) as described previously [11].
Statistical analysis
SASSAD, BSA, and serum biomarker levels were nor-
malized by log-transformation. Statistical comparisons 
were performed using Pearson correlations, Wilcoxon 
matched-pairs signed rank tests, and unpaired two tailed 




Kappa Ig-FLCs levels in AD patients (n = 82) did not sig-
nificantly differ from kappa Ig-FLCs levels in non-atopic 
controls (n = 49; median 23.63 µg/ml, IQR: 16.45–30.43, 
vs. 15.66  µg/ml, IQR: 10.95–21.38; Fig.  1a). Kappa Ig-
FLC concentrations slightly decreased to 16.20  µg/ml 
(median, IQR: 10.00–24.00) after treatment in the 32 
admitted patients, although this was not statistically 
significant (Wilcoxon matched-pair signed rank test; 
Fig. 1b). Kappa Ig-FLC levels measured before treatment 
did not correlate with disease severity measured by SAS-
SAD (r = 0.12, p = 0.30) and BSA (r = −0.05, p = 0.65). 
Kappa Ig-FLC levels did also not correlate to serum 
TARC (r = 0.19, p = 0.30) or any other serum biomarker 
(data not shown).
Total IgE levels
Total IgE levels were significantly higher in AD patients 
(median 2702.00  kU/l, IQR: 921.3–8579) than in non-
atopic controls (median 34.05  kU/l, IQR: 12.90–75.05; 
Fig.  1a). Total IgE levels did not change after treatment 
(Fig. 1b). Total IgE levels did not correlate with kappa Ig-
FLC levels (r = 0.15, p = 0.18; data not shown).
Disease severity
All 32 patients that were treated during a clinical 
admission, showed significant improvement. SAS-
SAD decreased from 33.0 (median, IQR: 28–44) to 9.0 
(median, IQR: 5–16); BSA decreased from 54% (median, 
IQR: 36–69) to 15.0% (median, IQR: 3.8–23.3; Fig. 1c).
Serum TARC, PARC, sIL-2R and IL-22 levels signifi-
cantly decreased in all 32 patients (Fig. 1c).
Discussion
This study shows that there are no differences between 
kappa Ig-FLC levels in adult AD patients and non-atopic 
controls. In addition, we found no correlation between 
kappa Ig-FLCs levels and disease severity, BSA or serum 
biomarker levels.
Previous studies have suggested a role for Ig-FLCs in 
the pathophysiology of allergic diseases. Serum levels of 
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Ig-FLCs were found to be upregulated in allergic and non-
allergic rhinitis [12, 13], and an Ig-FLC antagonist was found 
to abrogate airway obstruction, hyperresponsiveness, and 
pulmonary inflammation in a murine model of asthma [14]. 
Serum kappa Ig-FLCs levels were shown to be significantly 
increased in children with AD compared to normal controls 
[5, 6]. Moreover, a correlation of kappa Ig-FLCs with disease 
severity was shown in children with severe AD [5]. In con-
trast to our a priori hypothesis, these findings were not 
reproducible in adult AD patients. Although kappa Ig-FLCs 
may play a role in AD in children, in the current research no 
evidence for Ig-FLC involvement in adult AD was found.
Remarkably, two healthy controls showed high serum 
kappa Ig-FLC levels (94.0 and 180.9 µg/ml, respectively). 
Fig. 1 Serum kappa Ig‑FLC and total IgE levels in AD patients and non‑atopic controls. a A Students’ t test showed no significant differences 
between the levels of kappa Ig‑FLCs in AD patients (n = 82; median 23.63 µg/ml, IQR: 16.45–30.43) compared to non‑atopic controls (n = 49; 
15.66 µg/ml, IQR: 10.95–21.38). Total IgE levels in AD patients (median 2702.00 kU/l, IQR: 921.3–8579) were significantly higher compared to non‑
atopic controls (median 34.05 kU/l, IQR: 12.90–75.05), according to a students’ t test (p = 0.0001). b, c Kappa Ig‑FLC concentrations showed a small 
non‑significant decrease from 23.63 to 16.20 µg/ml (median) after treatment (p = 0.17). No significant changes were observed between total IgE 
levels before and after treatment (p = 0.22) (b). Disease severity measured by SASSAD and BSA, significantly decreased during a clinical admission 
and treatment with topical steroids (n = 32). Levels of serum biomarkers TARC, PARC, sIL‑2R, and IL‑22 also significantly decreased. c Data were 
analyzed using a Wilcoxon matched‑pairs signed rank test
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Although these high levels may be the result of the pres-
ence of another, non-atopic disease, these subjects were 
apparently healthy and reported no medical conditions. 
Elevated serum Ig-FLC levels have been shown in mul-
tiple myeloma [15], systemic lupus erythematosus [16], 
and rheumatoid arthritis patients [17], and were also 
reported shortly after marathon running [18].
Total IgE levels were analyzed in addition to serum 
kappa Ig-FLC. Total IgE did not decrease during treat-
ment and is therefore not suitable as a biomarker for mon-
itoring disease severity. Contrary to IgE, serum TARC, 
PARC, sIL-2R and IL-22 levels significantly decreased 
during treatment (Fig. 1c). This confirms previous reports, 
showing that these biomarkers reflect disease severity in 
AD patients [10]. Considering the heterogeneous charac-
ter of AD, with multiple immunologic pathways playing 
a role, we have previously suggested using a panel of bio-
markers, including the above mentioned [10]. This panel 
may be able to cover multiple immunologic pathways, and 
may be more suitable for assessing disease severity in AD 
compared to a single biomarker.
In conclusion, this study shows that there are no dif-
ferences in serum kappa Ig-FLC levels between adult 
patients suffering from moderate to severe AD compared 
to non-atopic controls. Moreover, serum kappa Ig-FLC 
levels do not correlate with disease severity determined 
by clinical outcome measures or serum biomarkers. 
Additionally, serum kappa Ig-FLC levels do not decrease 
during effective treatment of AD.
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